Rejected at 9:33 p.m. Jan, 06, 2026 ] by gnigam
Author: ishwarm
Co-authors: andrewmathias8
Related Note: 1488768082952 1
Rationale for change

DOACs are indicated in non-valvular afib thus it stands to reason that this cloze should specify non-valvular afib especially when the "Extra" text specifies that warfarin is indicated for valvular afib
Source: AMBOSS - https://next.amboss.com/us/article/GS0Baf?q=atrial%20fibrillation#Xp19L30

Rejection reason

Thank you for this suggestion. Already being deliberated upon in another suggestion!

Text Text
Extra
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Sketchy
Sketchy 2
Sketchy Extra
Picmonic
Empty field
Pixorize
Physeo
Bootcamp
OME
Additional Resources
One by one
Empty field
#AK_Step2_v12::#SketchyNeurology::07_Neurovascular::02_Ischemic_Stroke::01_Ischemic_Embolic_Stroke #AK_Step2_v12::#UWorld::Step::6881 #AK_Step2_v12::#AMBOSS::7C04tR #PANCE::EOR::Family_med #AK_Other::#AK_Original_Decks::Step_1::Zanki_Pharmacology #AK_Step1_v12::#UWorld::Step::15390 #AK_Step1_v12::#Low/HighYield::1-HighYield #AK_Other::Only_Step_1&2_Overlap #AK_Step2_v12::#SketchyIM::02_ECG_Interpretation_&_Arrhythmias::05_Retired_Lessons::04_Tachycardia::02_Narrow_Complex_Tachycardia_AFib_AFlutter_SOA_MAT_SOAP_[OLD_VERSION] #AK_Step2_v12::!Shelf::IM #AK_Step2_v12::#B&B::07_Hematology_and_Oncology::02_Coagulation::05_Anticoagulants::Extra #AK_Step1_v12::#B&B::12_Hematology::01_Hemostasis::07_Anticoagulant_Drugs::Extra #AK_Step1_v12::#NinjaNerd::06_Cardiovascular::04_Pharmacology::02_Warfarin_(MOA,_Indications,_AR,_CI) #PANCE::EOR::IM #AK_Step2_v12::#UWorld::COMLEX::101238 #AK_Step1_v12::#OME::Clinical::Internal_Medicine::Hematology-Oncology::Approach_To_Bleeding #AK_Step1_v12::#Pixorize::03_Pharmacology::11_Heme_Pharm::09_Factor_Xa_Inhibitors_(Apixaban/Rivaroxaban/Edoxaban) #AK_Step1_v12::#UWorld::COMLEX::26286 #AK_Step1_v12::#SketchyPharm::03_Blood_&_Inflammation::01_Anticoagulants_&_Thrombolytics::01_Heparin,_LMWH,_fondaparinux,_direct_thrombin_inhibitors,_Xa_inhibitors #AK_Step2_v12::#UWorld::#UWSA1 #AK_Step1_v12::#Physeo::^physeo_image_update #AK_Step2_v12::#UWorld::Step::4452 #AK_Step2_v12::#AMBOSS::TB06Zi #AK_Step1_v12::#NinjaNerd::09_Hematology::02_Pathology::15_Antiplatelets,_Anticoagulants,_and_Thrombolytics #AK_Step2_v12::#B&B::02_Cardio::01_Arrhythmias::03_Atrial_Fibrillation_and_Flutter #AK_Step1_v12::#FirstAid::10_Hematology_and_Oncology::05_Pharm::04_Direct_coagulation_factor_inhibitors::*Direct_Factor_Xa_Inhibitors #AK_Step1_v12::#B&B::16_Neuro::03_Neurovascular_Disorders::06_Treatment_of_TIA/Stroke::Extra #AK_Step1_v12::#NinjaNerd::06_Cardiovascular::04_Pharmacology::04_Direct_Acting_Oral_Anticoagulants_(DOACs)_(MOA,_Indications,_AR,_CI) #AK_Step2_v12::#SketchyIM::02_ECG_Interpretation_&_Arrhythmias::04_Tachycardia::04_Narrow_Complex_Tachycardia:_AFib_&_AFlutter_Management #AK_Step1_v12::#NinjaNerd::06_Cardiovascular::04_Pharmacology::03_Heparin_(MOA,_Indications,_ADR,_CI) #PANCE::EOR::EM #AK_Step2_v12::#SketchyNeurology::07_Neurovascular::04_Stroke_Management::01_Ischemic_Stroke_Treatment #PANCE::CARDIO::conduction_disorders/dysrhythmias #AK_Step1_v12::#NinjaNerd::04_Pharmacology::01_Basics::03_Antiplatelet,_Anticoagulant,_Thrombolytic_Agents #AK_Step1_v12::#Physeo::09_Pharm::17_Hem/Onc_Pharm::02_DirectThrombinInhibitors_DirectFactorXaInhibitors #AK_Step1_v12::#Bootcamp::Hematology_and_Oncology::07_Coagulation_and_Fibrinolysis::10_Anticoagulation #AK_Step2_v12::#Bootcamp::Medicine::01_Cardiology::02_Valvular_Disease::11_Complications_and_Critical_Interventions